Twist Bioscience (NASDAQ:TWST) Trading Up 5.5%

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) shares shot up 5.5% during trading on Thursday . The company traded as high as $46.84 and last traded at $46.59. 123,862 shares changed hands during trading, a decline of 88% from the average session volume of 1,013,920 shares. The stock had previously closed at $44.17.

Analyst Ratings Changes

A number of brokerages have recently commented on TWST. The Goldman Sachs Group upped their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, July 9th. Barclays lowered their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 5th. Guggenheim initiated coverage on shares of Twist Bioscience in a research note on Tuesday, June 4th. They issued a "buy" rating and a $53.00 target price on the stock. Evercore ISI upped their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an "outperform" rating in a research note on Friday, May 3rd. Finally, Robert W. Baird upped their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $48.22.

Twist Bioscience Price Performance

The stock has a market capitalization of $2.63 billion, a P/E ratio of -13.36 and a beta of 1.80. The company's 50 day simple moving average is $49.17 and its two-hundred day simple moving average is $42.59.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience's quarterly revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.01) earnings per share. On average, research analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Dennis Cho sold 709 shares of the company's stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the transaction, the insider now directly owns 78,996 shares in the company, valued at $3,154,310.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Dennis Cho sold 709 shares of the company's stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the transaction, the insider now directly owns 78,996 shares in the company, valued at $3,154,310.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,408 shares of the company's stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total transaction of $123,602.64. Following the transaction, the chief executive officer now owns 507,578 shares in the company, valued at $26,053,978.74. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,327 shares of company stock valued at $978,760. 3.92% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of the business. American International Group Inc. lifted its holdings in Twist Bioscience by 0.8% in the first quarter. American International Group Inc. now owns 28,506 shares of the company's stock valued at $978,000 after buying an additional 213 shares during the period. Caprock Group LLC lifted its holdings in Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company's stock valued at $387,000 after buying an additional 220 shares during the period. Arizona State Retirement System lifted its holdings in Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after buying an additional 308 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock valued at $457,000 after buying an additional 312 shares during the period. Finally, CWM LLC lifted its holdings in Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company's stock valued at $120,000 after buying an additional 524 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.